-
News | 2020.04.28
COVID-19 pandemic: The Institut Pasteur International Network collective effort
To this day, SARS-CoV2, the virus responsible for COVID-19 pandemic, has been identified in more than 180 countries. It unfolded a once-in-a-century public health crisis, through his extensive impact on global economy directly caused by confinement measures. To confront these challenges, the 32 member institutes of the Institut Pasteur International Network (IPIN) are swinging into...
-
Document de presse | 2020.05.07
Achilles’ heel for reseeding of the viral reservoir after stem cell transplantation in people with HIV
Current HIV treatments efficiently block viral multiplication but cannot cure infection as they do not target HIV infected cells. HIV cure or profound HIV remission have been described in three persons with HIV who underwent allogeneic stem cell transplantation to treat severe blood cancers. However, this procedure has not eradicated the virus in other persons. A work led by scientists from the...
-
News | 2020.07.20
i-Lab 2020 competition: two winners from the Institut Pasteur, one awarded a Grand Prix
On July 16, the i-Lab 2020 innovation competition unveiled the names of 73 winners, which this year included the D4Zin (Grand Prix) and AVATAR MEDICAL projects, both based on research carried out at the Institut Pasteur and supported by the Pasteur Microbes and Health Carnot Institute.Sponsored by the French Ministry of Higher Education, Research and Innovation and organized in partnership with...
-
Document de presse | 2021.01.19
COVID-19: a lentiviral vaccine candidate for intranasal administration provides sterilizing protection in animal models
Scientists from the Institut Pasteur-TheraVectys Joint Laboratory recently published in Cell Host & Microbe1 the results of tests, in two preclinical models, of a COVID-19 vaccine candidate using a lentiviral vector administered by nasal route. Their study demonstrates that the vaccine candidate induces antibody response with strong neutralizing activity against SARS-CoV-2, as well as...
-
Document de presse | 2022.06.15
COVID-19: Identification of broadly SARS-CoV-2 neutralizing monoclonal antibodies
Although the different SARS-CoV-2 variants currently in circulation are undoubtedly less severe in vaccinated individuals in the general population, immunocompromised people are at greater risk of developing severe forms of COVID-19. Monoclonal antibodies currently offer the best approach, both as a preventive and curative treatment for these patients. Scientists from the Institut Pasteur and...
-
Document de presse | 2023.01.13
Using paleogenomics to elucidate 10,000 years of immune system evolution
Scientists from the Institut Pasteur, Université Paris Cité, the CNRS and the Collège de France have used paleogenomics to trace 10,000 years of human immune system evolution. They analyzed the genomes of more than 2,800 individuals who lived in Europe over the past ten millennia. They were able to date the increase in frequency of most of the mutations that are advantageous in defending against...
-
Document de presse | 2023.01.25
Discovery of a circovirus involved in human hepatitis
Scientists from the Institut Pasteur, Necker-Enfants Malades Hospital (AP-HP), Inserm in the Imagine Institute, Université Paris Cité and the Alfort National Veterinary School (EnvA) have identified a previously unknown species of circovirus, provisionally named human circovirus 1 (HCirV-1). Circoviruses are a family of small, highly resistant DNA viruses that were initially identified in 1974 in...
-
Document de presse | 2023.07.27
Remission from HIV-1 infection: discovery of broadly neutralizing antibodies that contribute to virus control
Some HIV-1 carriers who have received an early antiretroviral treatment during several years are able to control the virus for a long term after treatment interruption. However, the mechanisms enabling this post-treatment control have not been fully elucidated. For the first time, teams of scientists from the Institut Pasteur, Inserm and the Paris Public Hospital Network (AP-HP), supported by...
-
News | 2023.12.18
Climate and health: the latest on a silent epidemic
While the main outcome of COP28 was an agreement calling on the parties to "transition away from fossil fuels" with the aim of limiting climate change, it was also the first COP to include a Health Day. Rising global temperatures, extreme meteorological phenomena and ecosystem change are not merely environmental concerns. They are catalysts of a silent epidemic that is affecting human health....
-
News | 2023.09.05
HIV-AIDS: broadly neutralizing antibodies, stars of the lab
Highly promising, broadly neutralizing antibodies can react with the vast majority of HIV particles to cause their destruction by the body. However, the latter would have to be able to produce equally effective antibodies...